BFRG News

Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +19.05% and +10.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares movedread more...

Here is how Bullfrog AI Holdings Inc. (BFRG) and Agilent Technologies (A) have performed compared to their sector so far this year.

BullFrog AI Holdings is trading higher Wednesday after SEC filings revealed substantial open-market share purchases by its CEO and CFO.read more...

Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG) sharesread more...

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

The artificial intelligence boom is entering a new phase, one defined less by infrastructure and more by real-world application. Nowhere is that shift more visible than in biotech, where data, diagnostics, and drug discovery are converging into a high-stakes innovation race. Recent developments across public markets show both the promise and the volatility of this transition, as capital flows toward platforms capable of turning complex biological data into actionable outcomes. $KBLB, $BFRG, $RZLV, $ELAB, $EEIQ, $ITRM

Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of artificial intelligence value creation may emerge: healthcare. In a series of trades during late March, Wood aggressively reduced exposure to mega-cap technology and semiconductor names while building a high-conviction position in Tempus AI (NASDAQ:TEM). The move reflects a broader thesis she has increasingly emphasized: the most underestimated frontier for AI innovation is healthcare. As AI infrastructure becomes crowded and capital-intensive, ARK is rotating toward companies applying AI to real-world, high-stakes problems like disease detection, drug development, and clinical decision-making. $ROKU, $NVDA, $TSM, $TSLA, $BFRG, $TGNT